Zacks Research Downgrades Takeda Pharmaceutical (NYSE:TAK) to Hold

Key Points

• Zacks Research downgraded Takeda Pharmaceutical from “strong buy” to “hold,” although the broader analyst consensus remains “Moderate Buy,” with two Buy and two Hold ratings.
• Takeda reported quarterly earnings of $0.95 per share, beating estimates of $0.41, while revenue of $7.50 billion exceeded the $7.13 billion consensus forecast.
• Insiders sold 627,457 shares worth approximately $11.0 million over the past 90 days; insiders own just 0.04% of the company, while institutional investors hold 9.17%.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued on Thursday, Zacks reports.

Several other brokerages have also recently issued reports on TAK. Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Weiss Ratings raised shares of Takeda Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, September 11th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of "Moderate Buy".

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $17.87 on Thursday. The company has a market cap of $57.25 billion, a P/E ratio of 52.55 and a beta of -0.07. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $19.10. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm's fifty day moving average is $18.06 and its two-hundred day moving average is $17.24.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.54. The firm had revenue of $7.50 billion during the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, analysts anticipate that Takeda Pharmaceutical will post 1.56 EPS for the current fiscal year.

Insider Buying and Selling at Takeda Pharmaceutical

In other news, insider Andrew Plump sold 116,191 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the transaction, the insider owned 145,465 shares of the company's stock, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lauren Duprey sold 34,535 shares of the firm's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the sale, the insider owned 191,522 shares of the company's stock, valued at approximately $3,550,817.88. This represents a 15.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 627,457 shares of company stock valued at $10,981,175. Corporate insiders own 0.04% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. SHP Wealth Management purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $42,000. Harbour Investments Inc. increased its stake in Takeda Pharmaceutical by 300.3% in the fourth quarter. Harbour Investments Inc. now owns 4,612 shares of the company's stock worth $72,000 after purchasing an additional 3,460 shares during the period. Manchester Capital Management LLC lifted its position in shares of Takeda Pharmaceutical by 91.4% during the fourth quarter. Manchester Capital Management LLC now owns 4,649 shares of the company's stock worth $72,000 after purchasing an additional 2,220 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Takeda Pharmaceutical by 30.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company's stock worth $81,000 after purchasing an additional 1,215 shares during the last quarter. Finally, Walkner Condon Financial Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at $186,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda's portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.